ReviewPediatric nephrology (Berlin, Germany)2016
Primary hypertension is a disease of premature vascular aging associated with neuro-immuno-metabolic abnormalities.
Review in Pediatric nephrology (Berlin, Germany), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 48 citations in OpenAlex.
- Unsupervised characterization of 100,272 EHR patients identifies high-risk groups and comorbidities linked to premature aging.NPJ digital medicine · 2026Article
- Leptin, Interleukin 6, and Vascular Endothelial Growth Factor as Potential Predictors of Primary Hypertension in Children and Adolescents with Obesity.International journal of molecular sciences · 2026Article
- Ferroptosis in Cardiovascular Diseases and Ferroptosis-Related Intervention Approaches.Cardiovascular drugs and therapy · 2025Review
- Blood Pressure Variability and Low-Grade Inflammation in Pediatric Patients with Primary Hypertension.Journal of clinical medicine · 2025Article
- Cardiovascular Assessments in Children and Adolescents With Hypertension.Reviews in cardiovascular medicine · 2025Review
- Monocyte-to-Neutrophil Ratio as an Immunological Marker of Left Ventricular Hypertrophy in Children with Primary Hypertension.Journal of clinical medicine · 2025Article
- Association of Subclinical Inflammation Markers with Primary Hypertension in Children-A Systematic Review with Meta-Analysis.Journal of clinical medicine · 2025Review
- A Multivariate prediction model for amlodipine therapeutic efficacy in pediatric primary hypertension.Frontiers in endocrinology · 2025Observational
- Review
- Pathophysiology of primary hypertension in children and adolescents.Pediatric nephrology (Berlin, Germany) · 2024Review
- Effects of Puberty on Blood Pressure Trajectories - Underlying Processes.Current hypertension reports · 2023Review
- Immunological mechanisms of arterial damage in pediatric patients with primary hypertension.Central-European journal of immunology · 2023Review
- 24-hour central blood pressure and immune system activation in adolescents with primary hypertension - a preliminary study.Central-European journal of immunology · 2022Article
- Serum Sclerostin Is Associated with Peripheral and Central Systolic Blood Pressure in Pediatric Patients with Primary Hypertension.Journal of clinical medicine · 2021Article
- Serum Periostin as a Potential Biomarker in Pediatric Patients with Primary Hypertension.Journal of clinical medicine · 2021Article
- Obesity, metabolic syndrome, and primary hypertension.Pediatric nephrology (Berlin, Germany) · 2021Article
- Arterial stiffness in children with primary hypertension is related to subclinical inflammation.Central-European journal of immunology · 2021Article
- Leukocyte matrix metalloproteinase and tissue inhibitor gene expression patterns in children with primary hypertension.Journal of human hypertension · 2020Article
- Markers of endothelial injury and subclinical inflammation in children and adolescents with primary hypertension.Central-European journal of immunology · 2019Article
- Why should we screen for arterial hypertension in children and adolescents?Pediatric nephrology (Berlin, Germany) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is an increasing amount of data indicating that primary hypertension (PH) is not only a hemodynamic phenomenon but also a complex syndrome involving abnormal fat tissue distribution, over-activity of the sympathetic nervous system (SNS), metabolic abnormalities, and activation of the immune system. In children, PH usually presents with a typical phenotype of disturbed body composition, accelerated biological maturity, and subtle immunological and metabolic abnormalities. This stage of the disease is potentially reversible. However, long-lasting over-activity of the SNS and immuno-metabolic alterations usually lead to an irreversible stage of cardiovascular disease. We describe an intermediate phenotype of children with PH, showing that PH is associated with accelerated development, i.e., early premature aging of the immune, metabolic, and vascular systems. The associations and determinants of hypertensive organ damage, the principles of treatment, and the possibility of rejuvenation of the cardiovascular system are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.